In 2023, the global market for pathology instruments is expected to be worth US$3.65. From 2023 to 2033, the global demand for pathology tools is expected to grow at a CAGR of 4.5%. According to a recent report by market research and competitive intelligence firm Fact.MR, factors including the global increase in the prevalence of bacterial and viral diseases as well as chronic illnesses might be linked to market expansion.
Globally, cancer ranks as the second most common cause of death. It is anticipated that over 30 million people will receive a cancer diagnosis by 2040. The danger of heart problems is rising as diabetes becomes more common. Globally, the number of cardiovascular disease cases is rising quickly. Consequently, when the prevalence of chronic illnesses rises, the adoption rate of early disease detection, which is subsequently driving target market growth.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 early disease detection, which is subsequently driving target market growth.𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.factmr.com/connectus/sample?flag=S&rep_id=8357
It is anticipated that widespread adoption of state-of-the-art instruments for anatomic pathology, such as digital microscopes and staining systems, will significantly improve pathology procedures. Because digital imaging systems offer greater specificity and precision than traditional methods, the market for pathology devices is expanding.
What Market Trends Are Driving Growth for Pathology Instrument Providers?
“Rising Skin Cancer Cases Fuel Demand for Histopathology Instruments”
The growing prevalence of melanoma is raising concern among the public, as it remains one of the most severe forms of skin cancer.
According to the United Nations Environment Program, approximately 200,000 new cases of malignant melanoma are reported each year. The Skin Cancer Foundation notes that melanoma diagnoses have surged by 53% over the past decade.
Increased referrals from general practitioners and heightened public awareness are driving demand for histological analysis of melanoma. This trend underscores the need for a standardized and comprehensive approach to melanoma histology, boosting demand for histopathology instruments.
What Limits Pathology Instrument Sales?
“Refurbished Devices Impact Market Growth”
High error rates across testing phases and the availability of refurbished pathology instruments are key factors restraining sales.
- Pre-analytic errors: 32% to 75%
- Analytic errors: 13% to 32%
- Post-analytic errors: 9% to 31%
Larger labs handling over 20,000 specimens face higher discrepancies. Companies like LabX and ReScience offer refurbished systems, making them a cost-effective choice for smaller labs in developing regions, limiting demand for new instruments.
U.S. Pathology Instrument Strategies
In 2022, NIH reported 15-20% of U.S. breast cancer patients were HER-2 negative, with 287,850 new cases.
Rising disease cases, better healthcare, and tech advancements in pathology drive market growth. AI, digital tools, and upgraded labs boost profits for manufacturers.
In 2021, Roche and PathAI partnered to integrate image analysis algorithms into Roche’s NAVIFY Digital Pathology platform, enhancing diagnostics.
Competitive Landscape
Leading pathology instrument companies are advancing technologies to strengthen market dominance and boost revenue. Key strategies include local supply, regional expansion, and pricing adjustments.
In March 2022, Illumina launched the ‘TruSight Oncology (TSO)’ genomic profiling kit in Europe. This in-vitro tool analyzes multiple genes and biomarkers, helping clinicians personalize cancer treatment by identifying unique molecular patterns.
Comments
0 comment